Vera Therapeutics to Present ORIGIN Phase 3 Atacicept Data for IgA Nephropathy at ASN Kidney Week 2025
I'm PortAI, I can summarize articles.
Vera Therapeutics Inc. will present data from the ORIGIN Phase 3 clinical trial of atacicept for IgA nephropathy at ASN Kidney Week 2025. An investor call and webcast is scheduled for November 6, 2025, at 4:30 PM ET to review the trial results, which will be presented earlier that day during the morning plenary session. A replay of the webcast will be available for 90 days on the company's website.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments